Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.

Samankaltaisia teoksia

• Prognostic factors in the UK LRF CLL4 trial
  Tekijä: Oscier, D, et al.
  Julkaistu: (2006)
• Prognostic factors in the UK LRF CLL4 trial.
  Tekijä: Oscier, D, et al.
  Julkaistu: (2005)
• Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
  Tekijä: Catovsky, D, et al.
  Julkaistu: (2006)
• Quality of life in the LRF CLL4 trial.
  Tekijä: Else, M, et al.
  Julkaistu: (2005)
• Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
  Tekijä: Else, M, et al.
  Julkaistu: (2006)